Proteinaceous inhibitors of proteolytic enzymes are widespread in both eukaryotes and prokaryotes (Laskowski and Kato, 1980) . In higher plants, several gene families have now been characterized, particularly the Ser proteinase inhibitors from the Leguminosae, the Solanaceae, and the Graminae (Garcia-Olmedo et al., 1987) . In the Solanaceae, two major gene families have been identified and designated as PPI-I and PPI-11. The PPI-I family is composed of isoinhibitors with native molecular masses of about 40 kD, which consists of five subunits, each with an apparent mass of 8.1 kD (Melville and Ryan, 1972) . Each subunit has a single reactive site for the Ser proteinase chymotrypsin. The PPI-11 family comprises isoinhibitors of 21 kD that are dimers, with each subunit containing two reactive sites. Any one reactive site can bind only to trypsin or to chymotrypsin and so a particular isoinhibitor either inhibits both trypsin and chymotrypsin or, more unusually, inhibits predominantly chymotrypsin ' This work was funded by the New Zealand Foundation for * Corresponding author; fax 61-6-356-1130.
Research, Science and Technology (contract No. C10311). (Bryant et al., 1976) . For both PPI-I and PPI-11, developmentally controlled and environmentally induced members have been discemed Keil et ai., 1989; Lorbeth et al., 1992) . For example, in potato tubers PPI-I1 protein accumulates up to levels of 15% in terms of total soluble protein (Bryant et al., 1976; Richardson, 1977) , and in tomato wounding induces the synthesis of PPI-I1 in leaves (Plunkett et al., 1982; Graham et al., 1985a Graham et al., , 1985b .
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As well as representatives of the PPI-I and PPI-I1 gene families, an additional class of proteinase inhibitory peptides has also been purified from potato (Pearce et al., 1982) . These are lower molecular mass proteins that contain only proteinase reactive site and inhibit either trypsin (designated potato trypsin inhibitor I) or chymotrypsin (PCI-I). Both of these inhibitors have been shown to have complete identity at the amino acid level to an intemal region of the full-length PPI-I1 protein and are proposed to arise from PPI-I1 by posttranslational modification . We have expressed a single member of the PPI-II gene family in tobacco and have identified both the full-length PPI-I1 and a lower molecular mass peptide as foreign proteins in transgenic tobacco. Here we present evidence that the lower molecular mass protein is identical to PCI-I, confirming that this peptide is derived from the full-length inhibitor by posttranslational modification. Furthermore, the use of transgenic tobacco as a model system to study the mechanism by which PCI-I arises from PPI-I1 is proposed, since the processing of a speafic isoinhibitor from a multigene family can be studied in isolation. Plant Physiol. Vol. 106, 1994 al., 1986) cloned into vector pmpK 110 was kindly supplied by Professor J. Schell (Max-Planck-Institute, Koln, Germany). To construct the plasmid for plant transformation, a 2.7-kb EcoRI restriction fragment from pmpK 110 that incorporated the 35S:PPI-II gene fusion was cloned into the unique EcoRI site of pBin 19 (Bevan, 1984) . The resultant plasmid was mobilized into the Agrobacterium tumefaciens strain LBA 4404 (Ditta et al., 1980) , and tobacco plants (Nicotiana tabacum) were produced using the leaf disc method as described by Horsch et al. (1985) .
Primary (&) transgenic plants that were confirmed as accumulating PPI-I1 protein using a polyclonal antibodybased ELISA (McManus et al., 1993) were selfed, and the progeny (RI) plants were used in experiments.
Purification of PPI-II Protein from Transgenic Tobacco
Leaves were harvested from RI plants that expressed PPI-I1 protein in excess of 0.2% of total soluble leaf protein, and (typically 80 g) were homogenized in 50 m~ Tris-HC1, pH 7.4, containing 25 m~ 2-mercaptoethanol (using a 3:l ratio of buffer:fresh weight of tissue). The resultant slurry was centrifuged at 10,OOOg for 15 min and the supematant was chromatographed through a 6 cm X 65 cm Sephadex G-25 (Pharmacia LKB, Ltd, Uppsala, Sweden) column with 10 m~ Tris-HCl, pH 8.0 as running buffer. Fractions containing chymotrypsin inhibitory activity were pooled and concentrated using an Amicon concentrator (molecular mass cutoff3000 kD; Amicon Division, Beverly, MA).
The concentrate (approximately 30 mL) was then chromatographed through a 5 cm x 100 cm Sephadex G-75 (Pharmacia) column, using 50 m~ sodium bicarbonate as column buffer, and 10-mL fractions were collected. Fractions that demonstrated chymotrypsin/trypsin inhibitory activity were pooled and concentrated. Each concentrate was either (a) subjected to SDS-PAGE and westem blotting for either antibody detection or N-terminal amino acid sequencing, or (b) purified further by ion-exchange and reverse-phase column chromatography for amino acid sequencing.
SDS-PACE and Western Blotting
SDS-PAGE was carried out essentially as described by Laemmli (1970) , with 10 to 20% polyacrylamide gradients used for separation. The production of polyclonal antibodies to PPI-I1 and the subsequent purification of IgG was as described by McManus et al. (1993) . Westem blotting and antibody detection was achieved by essentially using the method of Towbin et al. (1979) . Briefly, the PVDF membrane, after overnight transfer of the separated polypeptides, was blocked with a solution of 12.5% (w/v) low-fat milk powder (Anchor Products, Ltd, Auckland, New Zealand) in PBSalt and then 1% (v/v) goat serum (GIBCO-BRL) in PBSalt, each for 1 h at 25OC. After washing with 0.5% (v/v) Tween 20 in PBSalt, the membrane was incubated with rabbit anti-PPI-I1 IgG at a concentration of 100 pg/mL in PBSalt, and antibody binding was visualized using alkaline-phosphatase-conjugated goat anti-rabbit IgG (Sigma).
For N-terminal sequencing, the SDS-PAGE and electrophoretic trans-blotting procedures as outlined by Matsuidira (1987) were followed exactly.
Proteinase Inhibition Assays
Typically, 1 .O pg of bovine trypsin or chymotrypsin (Sigma) was assayed in 100 m~ Tris-HC1, pH 8.0, using N-benzoylarginine-p-nitroanilide (Sigma) or N-benzoyl-tyrosine-p-nitroanilide (Sigma), respectively, as substrates. The final assay volume was 200 pL, and the rate of reaction waj monitored at 415 nm using a Bio-Rad model 3550 Microplate Reader.
To assay for proteinase inhibition, column eluates were pre-incubated with each proteinase for 10 min at 24OC before the appropriate substrate was added. The final assay volume was again 200 pL, and the assay was monitored at 415 nm.
Purification of the Truncated PPI-I1 Protein for Amino Acid Sequencing
Pooled fractions, after Sephadex G-75 column chromatography, were concentrated using an Amicon concentrator, and the concentrate was diluted with 50 m~ sodium citrate buffer, pH 6.0, and then concentrated again. This procedure was repeated for an additional two times before application of the equilibrated concentrate onto a 5 cm x 30 cm carboxymethyl cellulose ion-exchange column (Bio-Rad) previously equilibrated with 50 m~ sodium citrate buffer, pl3 6.0. Bound protein was eluted within a linear gradient of O tl] 1.0 M NaCl in 50 m~ sodium citrate, pH 6.0, and fractions containing chymotrypsin inhibition were pooled and freeze-dried. The freeze-dried powder was resuspended in 0.1 % (\~/v) TFA and applied to a 1 cm X 30 cm Vydac C-18 reverse-phase column (Alltech, Deerfield, IL). Proteins were eluted within a linear gradient extending from 10% (v/v) acetonitrile in O. 1 % (v/v) TFA to 60% (v/v) acetonitrile in 0.1% TFA. Fractions that demonstrated chymotrypsin inhibition were pooled and freeze-dried. The reverse-phase-purified peptide was dissolved in 300 m~ Tris-HC1, pH 8.8, containing 6 M guanidineHCl, 2 m~ EDTA, and 10 m~ DTT and then incubated at 37OC for 3 h. After this time, iodoacetic acid was added to a final concentration of 40 m~, and the sample "as incubated for 45 min at 22OC in the dark. The reduced and alkylated protein was recovered by injection onto an 0.2 cm x 22 cm Aquapore RP300 column (Applied Biosystems, Foster City, CA) equilibrated with 90% solvent
tonitrile in water), followed by elution with a gradient extending from 10 to 70% solvent B. Elution was monitored at 214 nm, and the reduced and S-alkylated peptide was collected into a polypropylene tube and dried ir1 a Speedvac vacuum centrifuge. To obtain the N-terminal m d some intema1 sequence, the purified peptide was subjected to protease digestion. Here the dried material was dissolved in 40 pL of 100 m~ sodium phosphate, pH 7.5, then 0.5 pg of Asp-N protease (from Pseudomonas fragi; Boehringer-Mannheim, Mannheim, Germany) in 40 pL of water was added, and the peptide was digested for 2.5 h at 37OC. The Asp-N-cleaved peptides were isolated by acidification of the dii;est with 20% (v/v) TFA, followed by separation using micra-bore HPLC as described previously. Elution of the cleaved products was achieved using a gradient of 10 to 50% solvent B, with the eluate monitored at 214 nm.
Protein Sequence Analysis
Sequence analysis was performed with a model 470A gasphase sequencer, complete with an on-line phenylthiohydantoin amino acid analyzer (model 120A), using chemicals and programs supplied by the manufacturer (Applied Biosystems). For sequencing of the Asp-N-cleaved peptides that had been separated by micro-bore HPLC, each was applied to glass fiber discs (previously coated with polybrene) and then pretreated with two cycles of Edman degradation. For N-terminal sequencing of peptides that had been electroblotted onto PVDF membranes, the membrane pieces were placed directly into a Problott cartridge (Applied Biosystems).
RESULTS

Purification of PPI-II from Transgenic Tobacco Using Gel Filtration
Extracts from transgenic tobacco that had been shown by ELISA to accumulate PPI-I1 were fractionated using Sephadex G-75, and the occurrence of trypsin/chymotrypsin inhibition was assayed in each fraction ( Fig. 1 ). Three major regions of proteinase inhibition were observed within the fractions collected (designated as 'peaks" of proteinase inhibition), and the extent of the repression of either trypsin or chymotrypsin activity was determined (Table I) .
The first peak of inhibition (Fig. 1A ) co-migrates with PPI-I1 purified from potato ( Fig. 1, arrow) and represses predominantly chymotrypsin. It is not observed in nontransgenic tobacco (data not shown). The second peak (Fig. 1B) inhibits both trypsin and chymotrypsin and has subsequently been shown to comprise a mixture of isoinhibitors that are wound inducible in both transgenic and nontransgenic tobacco leaves (McManus et al., 1994) . Although the plants used in the experiments described here have not been deliberately wounded, we routinely observe the presence of these inhib- The elution of PPI-II purified from potato using these chromatography conditions is denoted by the arrow. itors in glasshouse-grown plants. Therefore, we attribute the wound response to such factors as insect damage or any attrition caused through plant care. In separate experiments we have deliberately wounded plants and found the extent of peak B to be greatly increased. In these plants the third peak (peak C) cannot readily be distinguished. Conversely, when transgenic and nontransgenic plants are grown in controlled environment cabinets and care taken to avoid plant damage, the trypsin/chymotrypsin inhibitory peak (peak B) is not detectable (data not shown). The third peak (Fig. IC) , identified here inhibits predominantly chymotrypsin at the concentration (5 &mL) of Ser proteinases used in the assay. This isoinhibifor is of lower molecular mass and by the gel-filtration procedure used here has a calculated size of approximately 5 to 6 kD. In common with peak A, it is always observed in transgenic tobacco and can be detected in nonwounded plants.
Identification of Full-Length and Truncated PPI-II Protein in Transgenic Tobacco
Each peak of proteinase inhibition revealed after Sephadex G-75 column chromatography was separated using SDS-PAGE, and using an antibody raised against PPI-11, the origin of each inhibitor was established ( Fig. 2A) . The antibody recognized a polypeptide of about 15 kD in peak A (Fig. 2A,  lane b) that co-migrates with PPI-I1 purified from potato ( Fig.  2A, lane a) . Although the expected subunit size of PPI-I1 has been given as 10,500 (Bryant et al., 1976) or 12,300 (Plunkett et al., 1982) , a polypeptide of about 15 kD is always detected as the subunit when using the SDS-PAGE protocol described here (McManus et al., 1993) . A polypeptide of about 5 to 6 kD in peak C (Fig. 2A, lane d) was also recognized by the anti-PPI-I1 antibody. The assignment of a molecular mass for this peptide is calculated from the use of aprotinin (6.5 kD) as one of the molecular mass standards. No recognition of the inhibitors in peak B by the antibody was observed (Fig.  2A, lane c) . We have recently purified these lower molecular mass native inhibitors from wounded tobacco leaves and found that when they are assayed at higher concentrations some cross-recognition with the anti-PPI-I1 IgG is observed. However, the level of recognition is much diminished compared to that observed for PCI-I, and at the concentration assayed here no recognition could be discemed. Plant Physiol. Vol. 106, 1994 a b c kD _24 -14 -6.5 B Figure 2 . Western blotting after separation using a 10 to 20% gradient SDS-PAGE. A, Detection of immunologically related polypeptides to PPI-II in the three major fractions of proteinase inhibitory activity identified by Sephadex G-75 column chromatography. a, PPI-II protein purified from potato; b, peak A; c, peak B; d, peak C. B, Comparison of the mobility of the PPI-II immunologically related polypeptides identified in peak A and peak C with a mixture of lower molecular mass inhibitory peptides purified from potato, a, Peak A; b, potato peptides; c, peak C. Polypeptides that are immunologically related to PPI-II are detected using anti-PPI-ll IgC, with antibody binding visualized using alkaline phosphatase-linked secondary antibodies.
To more accurately determine the molecular mass of the inhibitor recognized by the PPI-II antibody in peak C, its mobility using SDS-PAGE was compared with lower molecular mass inhibitory peptides that can be purified from potato using Sephadex G-75 column chromatography. Several lower molecular mass peptides can be purified from tubers and these include proteins designated as potato trypsin inhibitor I, PCI-I, and PCI-II , which have molecular masses of approximately 5.1, 5.4, and 5.7 kD, respectively. The lower molecular mass inhibitor recognized by the PPI-II antibody in transgenic tobacco co-migrated with these lower molecular mass peptides (Fig. 2B , compare lane b with lane c), confirming that it was in the range of around 5.1 to 5.7 kD. The range of molecular masses in the inhibitory peptides purified from potato (Fig. 2B, lane b) contributes to the more diffuse nature of the separated peptides after SDS-PAGE.
Confirmation that the Lower Molecular Mass Chymotrypsin Inhibitor Is Homologous to PCI-I
Initially, the lower molecular mass inhibitor partially purified by Sephadex G-75 (peak C) was subjected to N-terminal amino acid sequencing directly from PVDF membrane (data not shown). Eight residues were identified, and from this preliminary determination the lower molecular mass chymotrypsin inhibitor purified here has an N terminus that shares some identity with that determined for PCI-I.
To confirm that the lower molecular mass peptide is identical to PCI-I, the protein needed to be purified further and the N and C terminals, with some internal sequence, needed to be determined. To achieve this, the putative PCI-I peptide obtained by gel filtration (Fig. 1, peak C) was first subjected to ion-exchange column chromatography (Fig. 3A) . Here, two trypsin-inhibitory peaks eluted, but only a single inhibitory peptide eluted that both inhibited only chymotrypsin Figure 3 . Purification of the lower molecular mass chymotrypsin inhibitor identified in peak C after Sephadex G-75 column chromatography. A, Elution of proteinase inhibitory activity from a carboxymethyl-cellulose ion exchange column using a 0 to 1.0 M NaCl gradient. The chymotrypsin inhibitory peak (arrowhead) was purified further. B, C, Purification of chymotrypsin inhibitor identified in A using reverse-phase column chromatography. The peptide was bound to the column using 0.1% (v/v) TFA in water and eluted using a gradient of 10% (v/v) acetonitrile, 0.1% (v/v) TFA in water to 60% (v/v) acetonitrile, 0.1% (v/v) TFA in water. Detection of the purified inhibitor was by proteinase inhibition assay (B) or at 214 nm (C). D, The purified chymotrypsin inhibitor identified in B and C was cleaved using an Asp-N-specific proteinase, and the products were separated using reverse-phase column chromatography. Detection of the cleavage products was at 214 nm.
www.plantphysiol.org on October 15, 2017 -Published by Downloaded from Copyright © 1994 American Society of Plant Biologists. All rights reserved. (Fig. 3A, arrowhead) and was also recognized by the anti-PPI-I1 IgG (data not shown). These two properties are consistent with a PCI-I peptide. The two trypsin-inhibitory peaks are most likely wound-inducible peptides that have co-migrated with peak C during gel filtration and are now sufficiently pure to be detected in the proteinase inhibition assay. The PCI-I-like peptide was purified further using reverse phase column chromatography, where a chymotrypsin inhibitor profile (Fig. 3B, arrowhead) and (Fig. 3C ) revealed a single peak. To obtain maximum amino acid sequence data, the purified peptide was subjected to cleavage with an Asp-N protease, and the products were subjected to micro-bore reverse-phase column chromatography. Four sharp peaks and one broad peak were obtained (Fig. 3D) , and some amino acid sequence was determined for all of these (Fig. 4A) . The N-terminal sequences obtained from the Asp-N protease digestion products are, with the exception of peak 3, in perfect agreement with a predicted Asp-N protease digestion of PCI-I. Here, the protease should cleave at two sites within the PCI-I peptide (Asps4, Aspq6) to yield three fragments. Peak 1 from Figure 3D has been sequenced to completion and found to be completely homologous to the predicted C-terminal fragment (Fig. 4B, box C) . Peak 2 is the same fragment as peak 1, but has been only partly sequenced to determine its identity. At this stage it is not clear why there is a slight difference in mobility between peaks 1 and 2. Peaks 3 and 4 correspond to the second expected Asp-N-digested fragment (Fig. 4B, box B) . Peak 3 has most probably arisen by the protease cleaving C terminal to Aspartate to provide a digestion product with, again, a slightly altered mobility on the reverse-phase column (D. Christie, personal communication). Finally, the broader peak toward the end of the separation (Fig. 3D, arrowhead) contained sequence that is entirely identical to the predicted third (N-terminal) fragment from the Asp-N digestion ( Fig. 4B; box A) .
Together, when the amino acid sequences obtained from all the peaks are compared with a predicted PCI-I sequence from the PPI-I1 gene used to transform tobacco in this study, complete identity is observed (Fig. 4B, boxed regions) . Furthermore, all of the amino acid sequences identified fall within the PCI-I sequence. No sequence data have been obtained that are identical to regions of the PPI-I1 protein located either N or C terminal to PCI-I. To confirm this, two more sequencing cycles were carried out on the putative Cterminal fragment (Fig. 4A, peak l) , but no additional residues were detected (confirming that Ser'07 is the C-terminal amino acid).
To finally c o n f m that the purified inhibitor was PCI-I, the sequence was compared with one of the wound-inducible trypsin/chymotrypsin inhibitors from tobacco leaves. R I -# 1 (Pearce et al., 1993) . These wound-inducible inhibitors from tobacco are also approximately 5 to 6 kD in size, and one of these inhibits chymotrypsin only (Pearce et al., 1993; McManus et al., 1994) . The sequences obtained in this study are underlined and the arrows indicate sequence discrepancies between PCI-I and TTI-#1 (Fig. 4C) . Several can be noted Figure 4 . A, N-terminal sequence data obtained for each Asp-N-generated fragments separated using reverse-phase HPLC (in Fig.  3D) . 6, The published amino acid sequences of PPI-II, designated as PPI-II T (from Thornburg et a!., 1987), PPI-II K (from Keil et al., 1986) , and PCI-I (modified from Hass et al., 1982, to accommodate the N-terminal Arg). The boxed regions denote sequences that have been identified in this study (as shown in A). C, The published sequences of PCI-I (from B), TTI-#1 (from Pearce et al., 1993) , and PTI-I (from Hass et al., 1982) . The regions underlined denote sequences within PCI-I that have been identified in this study (as shown in A), and the arrows denote sequence differences within these regions between PCI-I and TTI-#l.
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www.plantphysiol.org on October 15, 2017 -Published by Downloaded from Copyright © 1994 American Society of Plant Biologists. All rights reserved. Plant Physiol. Vol. 106, 1994 within the sequences obtained in this study, confirming that the inhibitor purified here is PCI-I. A sequence comparison between PCI-I and PTI-I can also be made, and again there are several sequence discrepancies.
DISCUSSION
In potato the occurrence of (at least) three lower molecular mass Ser proteinase inhibitory peptides has been reported (Pearce et al., 1982) . One of these, designated PCI-I, has been sequenced and shown to have complete identity with a 52-amino acid intemal region (Pro56 to Ser'07) of PPI-I1 . Immunological studies also confirmed that PCI-I is related to PPI-I1 (Pearce et al., 1982) , so it has been postulated that this peptide arises from PPI-I1 by posttranslational modification. Evidence to support this hypothesis was provided when two cDNA clones were obtained from potato that were homologous to genes that encode PPI-I1 . In northem analysis experiments these cDNAs detected only a single mRNA transcript of 800 bp in potato tubers, and not one of 500 bp (the expected size of a transcript encoding PCI-I).
In this study we have taken a single member of the PPI-I1 gene family (Keil et al., 1986) and introduced it into tobacco. Analysis of the trypsin/chymotrypsin inhibition ratio suggests that the isoinhibitor encoded by this gene inhibits predominantly chymotrypsin, and comparison of the amino acid pairs at the two proteinase reactive sites confirms this observation (Leu36 G~u~~ at site I; L e~~~-A s n~~ at site 2). However, an antibody raised against PPI-I1 purified from potato tubers identified both the full-length protein and a lower molecular mass chymotrypsin inhibitor in transgenic tobacco.
The results presented here illustrate that this lower molecular mass chymotrypsin inhibitor is PCI-I and that it can originate from a member of the PPI-I1 multigene family when expressed in transgenic tobacco. To begin with, the lower molecular mass peptide when purified to homogeneity inhibited chymotrypsin almost exclusively. From the known amino acid sequence of the isoinhibitor encoded by the gene used to transform tobacco in this study (Keil et al., 1986) . PCI-1-(and not PTI-I) is the only inhibitor that can arise if the protein is posttranslationally processed in transgenic tobacco.
Subsequent amino acid sequencing of the N terminus and some intemal Asp-N protease-generated fragments from the purified lower molecular mass chymotrypsin inhibitor revealed complete identity with the published sequence of PCI-I . Importantly, the amino acid sequences obtained here also show significant differences from those identified and sequenced in wounded tobacco leaves (Pearce et al., 1993) . These observations, coupled with the specific recognition by the PPI-I1 antibody, confirm that the lower molecular mass chymotrypsin inhibitor is homologous to PCI-I and can have arisen only from the full-length PPI-I1 in transgenic tobacco. In common with observations from potato , only transcripts of 800 bp have been detected in transgenic tobacco expressing the PPI-I1 gene (McManus et al., 1993) . This observation further supports the notion that PCI-I derives from PPI-I1 by posttranslational modification.
. In terms of the mechanism by which this posttranslational modification occurs, it is more difficult to discern in potato, since PPI-I1 is encoded by a multigene family and there are several smaller peptides that are closely related to PCI-I. However, the expression in tobacco of only a single member of the multigene PPI-II family affords an ideal experimental system with which to study this posttranslationa I processing. It is probable that the truncated inhibitor is released from the full-length PPI-I1 by the action of specific peptidases. Early speculation on the nature of these peptidases was based upon the belief that any protease needs to be specific for an AsnPro linkage, since Pro was identified as the N-terminal amino acid of PCI-I . The Asn-Pro linkage arises from the amino acid sequence translated from the genomic clone of PPI-I1 characterized by Thomburg et al. (1987) . However, no peptidases capable of cleaving N terminal to Pro have been characterized in plants, so altem,&ive mechanisms of proteolytic processing have been proposed (Greenblatt et al., 1989 ). In the study described here, however, processing of the isoinhibitor encoded by the PPI-II gene used to transform tobacco would yield Arg at thl. N terminus of PCI-I, so an Asn-X-specific peptidase will suffice (where X is Arg). Peptidases with specificity pertaining to Asn-X cleavages are thought to occur in the vacuoles of cells from tomato and potato. Here they are involved in the processing of isoinhibitors of the PPI-I family. Of particular interest is that these peptidases are involved in processing woundinducible proteins, so they themselves may bv induced by wounding . Therefore, it may be that PCI-I is released by the action of specific peptidases in response to wounding. However, the sigruficiince of such proteolytic cleavage can, as yet, only be speculated upon.
The processing of precursor proteins to produce smaller, but fully functional, isoinhibitors does occur in tobacco. The processing of a precursor 42-kD PPI-11-related polypeptide to give a series of smaller isoinhibitors has been observed in stigmas from Nicotiana alata flowers (Atkinson et al., 1993) . A series of six small isoinhibitors has been identified in wounded leaves of N. tabacum (Pearce et al., 1903; McManus et al., 1994) , although a larger precursor protein has not yet been identified. Although these tobacco inhibitors (e.g. TTI-#1) and PCI-I share a high degree of sequence identity (Fig.  4C) , differences in antigenicity are quite appxent. In this study, an antibody raised against PPI-I1 strongly recognized PCI-I, whereas the purified tobacco inhibitors w'ere only very weakly recognized. Such discrimination using antibodies has also been observed previously (see Pearce et al. 1993 ). Modeling of both peptides to depict antigenic sites IJameson and Wolf, 1988) does reveal some differences (data not shown). In particular PCI-I has a highly antigenic C-terminal region that is absent from TTI-#1, suggesting differences in the conformation of each peptide. Such differences may also contribute to the slightly altered mobility of PCI-I using gel filtration when compared with the bulk of the wound-induced peak (Fig. 1, cf. peaks B and C). Because the woundinducible inhibitors that are native to tobacco differ both in their antigenicity and in their N-terminal amino acid residue (Asp rather than Arg), we anticipate that the peptidases involved in the processing of these native inh,bitors will be distinct from those proteins that mediate the processing of PPI-I1 to yield PCI-I in transgenic tobacco.
Accordingly, the accumulation of PPI-I1 and the mechanism by which the full-length protein is posttranslationally processed to yield PCI-I can be studied in transgenic tobacco. Currently, the location of PCI-I in transgenic tobacco and the characterization of specific peptidases that may be involved in proteolytic processing are being investigated.
